Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sucrose SCHEMBL350353 | 1.00 | CDK1 (0.68) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL8718558 | 1.00 | CDK1 (0.68) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL10910573 | 1.00 | CDK1 (0.68) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL8323806 | 0.99 | CDK1 (0.67) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL11039870 | 0.97 | CDK1 (0.68) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL23886158 | 0.96 | CDK1 (0.64) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL17801786 | 0.96 | CDK1 (0.64) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL15111218 | 0.95 | CDK1 (0.71) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL5490627 | 0.95 | CDK1 (0.71) | CDK1CCNB1CA2CA9MEN1 | |
| Sucrose SCHEMBL15111439 | 0.95 | CDK1 (0.71) | CDK1CCNB1CA2CA9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113016615-B | Tissue culture method for underground stems of perennial rice | 广西大学 | 2022-11-15 | — | — | CN | claimed |
| CN-113016615-A | Tissue culture method of underground stem of rice | 广西大学 | 2021-06-25 | — | — | CN | claimed |
| US-8623931-B2 | Protein-containing foams, manufacture and use thereof | BIOPOLYMER TECHNOLOGIES, LTD. (IL) | 2014-01-07 | — | — | US | claimed |
| EP-2403886-A2 | PROTEIN-CONTAINING FOAMS, MANUFACTURE AND USE THEREOF | Biopolymer Technologies, Ltd. (IL) | 2012-01-11 | — | — | EP | claimed |
| US-20100305227-A1 | Protein-Containing Foams, Manufacture and Use Thereof | EVERTREE (FR) | 2010-12-02 | — | — | US | claimed |
| WO-2010102297-A2 | PROTEIN-CONTAINING FOAMS, MANUFACTURE AND USE THEREOF | PARKER ANTHONY A (US) | 2010-09-10 | — | — | WO | claimed |
| US-5690855-A | USED IN MANUFACTURING RIGID FOAMS | SEALED AIR CORPORATION (US) | 1997-11-25 | — | — | US | claimed |
| WO-2024148222-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND INTEGRIN INHIBITORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148218-A2 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND TNF INHIBITORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024137353-A1 | METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND S1PR INHIBITORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024110667-A1 | TWO-STRAIN SYSTEM FOR PRODUCING OLIGOSACCHARIDES | DSM IP ASSETS B.V. (NL) | 2024-05-30 | — | — | WO | disclosed |
| US-11944594-B2 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | MURRAY AND POOLE ENTERPRISES LTD (GI) | 2024-04-02 | — | — | US | disclosed |
| US-11944595-B2 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | MURRAY AND POOLE ENTERPRISES LTD (GI) | 2024-04-02 | — | — | US | disclosed |
| US-4876088-A | Gamma-globulin injectable solutions containing sorbitol | GREEN CROSS CORPORATION (JP) | 1989-10-24 | — | — | US | disclosed |
| US-4510164-A | Process for producing intermediate moisture quick-cooking beans | MCCORMICK & COMPANY, INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0063858-B1 | LEUKOTRIENE ANALOGUES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Lilly Industries Limited (GB) | 1985-03-20 | — | — | EP | disclosed |
| US-4452824-A | Soft, frozen dessert formulation | UNILEVER, N.V. (NL) | 1984-06-05 | — | — | US | disclosed |
| US-4404193-A | HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1983-09-13 | — | — | US | disclosed |
| US-4055676-A | CORN SYRUP, PROPYLENE GLYCOL | THE QUAKER OATS COMPANY (US) | 1977-10-25 | — | — | US | disclosed |
| US-3952085-A | MAGNESIUM CHLORIDE, ACTIVATED ALUMINA | NL INDUSTRIES, INC. (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11944594-B2 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | ACE, ACE2, PCSK9 | CDK1 2287/4885CCNB1 851/4885CA2 47/4885 |
| US-11944595-B2 | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | PCSK9, HMGCR, FABP3 | CDK1 1433/4885CCNB1 663/4885CA2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.